A rising tide with liraglutide

A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging. This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of […]

CP news

Lorem Ipsum

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived…

Research events

Insight into Parkinson’s conference

PD Warrior, creators of the world’s most comprehensive rehabilitation program for people with Parkinson’s, is proud to bring the Parkinson’s community the INSIGHT 2022 online global conference. This year INSIGHT 2022 Living Brave with Parkinson’s celebrates Parkinson’s awareness by holding the longest World Parkinson’s Day conference ever!…

GCase and Parkinson’s: a new perspective

Recently new insights into how small defects in a region of DNA called the GBA gene could be affecting cell biology leading to Parkinson’s.

GCase: Mutants matter?

Tiny genetic variations in a region of DNA called the GBA gene are associated with an increased risk of developing Parkinson’s. The information in the GBA gene provides the instructions for making an enzyme (called GCase) which is involved with waste disposal inside of cells. Individuals with Parkinson’s who carry a […]